Discover what healthcare professionals (eHCPs) think about pharmaceutical products and their manufacturers, as it happens, through CREATION.co’s tracking updates. How are eHCPs responding to drug launch news? How are eHCPs talking about or engaging with the Top 50 pharma companies on social media? Each week, CREATION.co’s tracking updates bring you the latest insights from the conversation of eHCPs across the globe discussing these topics and more.
The Top 50 Pharmaceutical Companies mentioned by eHCPs on X
| December Rank | November Rank | Company Name | Total Mentions | Account Mentions | Account Retweets |
|---|---|---|---|---|---|
| 1 | 1 | Pfizer | 4,169 | 505 | 0 |
| 2 | 2 | Moderna | 2,801 | 98 | 2 |
| 3 | 4 | Johnson & Johnson | 1,148 | 244 | 6 |
| 4 | 5 | GSK | 421 | 128 | 38 |
| 5 | 3 | AstraZeneca | 418 | 233 | 4 |
| 6 | 9 | Novavax | 367 | 68 | 2 |
| 7 | 16 | BioNTech | 339 | 75 | 0 |
| 8 | 20 | Merck & Co | 266 | 176 | 8 |
| 9 | 14 | Gilead Sciences | 260 | 161 | 2 |
| 10 | 12 | Sanofi | 256 | 131 | 29 |
| 11 | 7 | Bayer | 243 | 49 | 8 |
| 12 | 11 | Roche | 205 | 57 | 10 |
| 13 | 6 | Novo Nordisk | 151 | 98 | 4 |
| 14 | 30 | Astellas | 147 | 117 | 0 |
| 15 | 15 | Novartis | 121 | 68 | 2 |
| 16 | 8 | Lilly | 101 | 77 | 0 |
| 17 | 21 | BMS | 94 | 77 | 1 |
| 18 | 18 | Amgen | 88 | 74 | 1 |
| 19 | 13 | Vertex | 83 | 81 | 6 |
| 20 | 17 | AbbVie | 82 | 40 | 7 |
| 21 | 10 | Abbott | 67 | 64 | 1 |
| 22 | 23 | Otsuka | 55 | 13 | 1 |
| 23 | 24 | Boehringer Ingelheim | 54 | 40 | 0 |
| 24 | 35 | Servier | 53 | 3 | 3 |
| 25 | 25 | Organon | 42 | 1 | 0 |
| 25 | 27 | Fresenius | 42 | 16 | 5 |
| 27 | 26 | Regeneron | 37 | 22 | 0 |
| 27 | 29 | Daiichi Sankyo | 37 | 16 | 4 |
| 29 | 19 | Takeda | 20 | 17 | 0 |
| 30 | 40 | Menarini | 16 | 10 | 0 |
| 31 | 33 | Merck KGaA | 14 | 11 | 1 |
| 32 | 31 | Ipsen | 11 | 3 | 0 |
| 33 | 37 | Bausch | 10 | 1 | 0 |
| 33 | 39 | Biogen | 10 | 4 | 0 |
| 35 | 44 | Jazz Pharmaceuticals | 8 | 6 | 1 |
| 36 | 50 | Sun | 7 | 3 | 0 |
| 37 | 33 | Eisai | 6 | 3 | 0 |
| 37 | 41 | CSL | 6 | 5 | 0 |
| 39 | 22 | Viatris | 5 | 1 | 0 |
| 39 | 28 | UCB | 5 | 2 | 2 |
| 41 | 42 | Chugai | 4 | 3 | 3 |
| 42 | 36 | Grifols | 3 | 0 | 0 |
| 43 | 32 | Teva | 2 | 2 | 1 |
| 44 | 50 | CSPC | 1 | 0 | 0 |
| 44 | 50 | Shanghai | 1 | 0 | 0 |
| 50 | 38 | Incyte | 0 | 0 | 0 |
| 50 | 42 | Horizon | 0 | 0 | 0 |
| 50 | 45 | Perrigo | 0 | 0 | 0 |
| 50 | 50 | Sino | 0 | 0 | 0 |
| 50 | 50 | Jiangsu Hengrui | 0 | 0 | 0 |
The latest insights from eHCPs mentioning the Top 50 Pharmaceutical Companies
The five pharmaceutical companies that were mentioned the most by eHCPs on X in December 2023 were Pfizer, Moderna, Johnson & Johnson, GSK and AstraZeneca.
CREATION.co identified 10,393 eHCP mentions of pharmaceutical companies in December 2023, decreasing by 7% over the previous month.
Between 05 and 09 December, eHCPs shared data and information from the San Antonio Breast Cancer Symposium. Oncologist Dr Paolo Tarantino thanked Merck for presenting data on the use of pembrolizumab in the treatment of ER+ breast cancer, calling it “helpful” research to aid in the treatment journey.
Joyce O'Shaughnessy presents sub analyses or KN756. Most benefit from neoadjuvant pembro for high-risk ER+ BC seen in the presence of node-positive disease, higher PD-L1 status and lower ER expression. Kudos to the study authors and @Merck for presenting these helpful data. pic.twitter.com/WC6QdoZc1T
— Paolo Tarantino (@PTarantinoMD) December 6, 2023
On 06 December, oncologist Hope Rugo shared a press release from Roche discussing positive phase 3 trial results for inavolisib.
First ever triplet ph 3 in HR+ MBC: press release Tuesday, data to be presented this Friday #sabcs23! Roche announces positive Phase III results for inavolisib combination in people with advanced HR+, HER2- MBC with a PIK3CA mutation @oncoalert https://t.co/wqiAehtzWE
— Hope Rugo (@hoperugo) December 6, 2023
On 09 December, paediatric oncologist Stephan Grupp celebrated Vertex Pharmaceuticals and Bluebird Bio for receiving FDA approval for sickle cell treatments, calling it “an amazing day”.
An amazing day with not one but two products FDA approved for sickle cell disease from @VertexPharma and from @bluebirdbio. Successful execution will drive provider choice and access. @CHOPCancerCntr https://t.co/3pfQgjAwxe
— Stephan Grupp MD PhD (@GruppSteve) December 9, 2023
On 21 December, neurologist Gustavo Saposnik shared a video reviewing 2023’s education and awareness of strokes. He thanked AstraZeneca and Bayer for their contributions throughout the year for “making the magic happen”.
📌What can a leader be proud of? Here is a superb example!"https://t.co/CpR8TP7OjD
It's all about passion, commitment, & teamwork. 🩷 @WorldStrokeEd Team! A special thanks to all our sponsors and supporters. You made the magic happen 🙏 @IpsenGroup @Danone @AstraZeneca @Bayer— Gustavo Saposnik 🇦🇷🇨🇦🌐 (@gsaposnik) December 21, 2023
The top shared links by eHCPs when mentioning a Top 50 pharma company discussed:
- A poster by ASE for Cardiac Amyloidosis, developed in collaboration with Pfizer.
- An article discussing Johnson & Johnson’s TAR-200 receiving FDA “Breakthrough Therapy” designation for treating a form of bladder cancer.
- An article mentioning Pfizer and Moderna’s COVID-19 vaccines receiving health registration in Mexico.
CREATION.co continues to analyse online eHCP conversation on a variety of topics including virtual congress, healthcare changes since the pandemic, product development and therapy area specific insights.
To stay up to date, you can sign up to CREATION.co’s monthly eJournal.
Methodology notes:
- In December 2023, CREATION Pinpoint® identified 10,393 healthcare professional authored posts on X (Twitter) from 3,600 individual eHCPs mentioning a Top 50 Pharmaceutical company (according to revenue).
- Data for this research was analysed from the online X conversations of eHCPs in all languages mentioning a Top 50 Pharmaceutical company between 01 – 31 December 2023.
- Unless otherwise specified, mentions of a company are not limited to its X account(s).
- In some cases, an X post may mention more than one company account (e.g. @abbottnews and @abbottglobal) – this only counts as one Company Mention and Account Mention.
- Johnson & Johnson was included as a whole, encompassing its pharmaceutical subsidiary, Johnson & Johnson Innovative Medicine (previously Janssen). In December 2023, 44 of these posts mentioned Johnson & Johnson Innovative Medicine or Janssen.
Click here to view all our Trackers
